Antiverse
Antiverse designs therapeutic antibodies for difficult drug targets using generative AI, engineered cell lines and in-house laboratory testing.
$9.3MSeries A
LeadSV
Soulmates Ventures
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Healthtech · Jan 1, 2026
Soulmates Ventures is a Prague sustainability investor whose own portfolio identifies Antiverse, FluoSphera and Rightcharge.
Recorded funding activity
Rightcharge manages fleet charging and payments. Antiverse develops antibodies using models and laboratories, while FluoSphera develops human-based preclinical testing. The recorded companies retain their different mechanisms and financing events.
Sources
- Rounds participated in
- 2
- Confirmed lead rounds
- 1 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $10.7M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionFluoSphera
Develops human-based preclinical platform for drug safety and efficacy testing
€1.2MUndisclosed
Role not disclosed